FDA approves Applied Pharmaceutical’s IND application for APS03118
APS03118 is a second generation selective rearranged during transfection (RET) inhibitor that targets patients suffering with non-small cell lung cancer, breast cancer, ovarian cancer, thyroid cancer, colorectal cancer,